Treatment Algorithms for Crohn's Disease
- 1 September 2020
- journal article
- review article
- Published by S. Karger AG in Digestion
- Vol. 101 (SUPPL 1), 43-57
- https://doi.org/10.1159/000506364
Abstract
Background:Treatment of Crohn's disease (CD) patients is complex as therapy choices depend on a variety of factors, such as location and severity of inflammation, disease behavior (inflammatory, stricturing or penetrating) but also comorbidities, extra-intestinal manifestations, the patient's age, and previous therapies. Subsequently, the choice of treatment should be tailored to the individual patient.Summary:This article gives the reader therapy algorithms as a guide through different CD scenarios to support the physician's decision making. New compounds introduced in CD therapy in recent years justify such an update on standard approaches. Ustekinumab and vedolizumab and their positions within the treatment options are discussed. Fistulizing perianal disease and postoperative medical prophylaxis are depicted in separate chapters with own algorithms.Key Messages:In recent years, a variety of new drugs became available to treat patients with CD - especially those who are antitumor necrosis factor (TNF) experienced with ongoing inflammation. The definitive role of vedolizumab and ustekinumab is not yet fully clarified. However, with the advantage of good safety profiles over TNF-inhibitors, these drugs will be more frequently used in the near future, also as first-line biologicals, compared to TNF-inhibitors. Concerning treatment of fistulizing disease, the knowledge of the exact anatomy of the fistula is of major importance. An interdisciplinary discussion involving gastroenterologists, surgeons, and in some cases gynecologists may help to optimize the treatment plan. Regarding the postsurgical setting in CD patients, according to the very recent Cochrane Network meta-analysis, mesalazine should be at least positioned equivalent to thiopurines and TNF-inhibitors, as shown in our algorithm.This publication has 74 references indexed in Scilit:
- Tumor Necrosis Factor Inhibitors for Inflammatory Bowel DiseaseThe New England Journal of Medicine, 2013
- Vedolizumab as Induction and Maintenance Therapy for Crohn's DiseaseThe New England Journal of Medicine, 2013
- Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatmentGut, 2013
- Development of the Crohnʼs disease digestive damage score, the Lémann scoreInflammatory Bowel Diseases, 2011
- Infliximab, Azathioprine, or Combination Therapy for Crohn's DiseaseThe New England Journal of Medicine, 2010
- Meta‐analysis: factors predicting post‐operative recurrence with placebo therapy in patients with Crohn’s diseaseAlimentary Pharmacology & Therapeutics, 2008
- Type I interferons for induction of remission in ulcerative colitisPublished by Wiley ,2007
- Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM TrialGastroenterology, 2007
- The Montreal classification of inflammatory bowel disease: controversies, consensus, and implicationsGut, 2006
- AGA technical review on perianal Crohn’s diseaseGastroenterology, 2003